[{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Acquires Rights to Trademarks of Three Diabetes Drug Brands in India from AstraZeneca","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."}]

Find Clinical Drug Pipeline Developments & Deals for Dapagliflozin Propanediol Monohydrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern r...

                          Brand Name : Xigduo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 28, 2021

                          Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          02

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : AstraZeneca India has granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name Oxra. Sun Pharma also gained the rights to promote and distribute the Oxramet (Dapagliflozin + Metformin) and Oxraduo (Dapagliflozin + Saxagli...

                          Brand Name : Oxra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 28, 2021

                          Lead Product(s) : Dapagliflozin Propanediol Monohydrate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank
                          Close
                          4